Thus, although we observed that LY2874455 has an extraordinary effect on inhibiting FGFs/CCND1 amplification, it is essential to treat the cancer cells with CCND1 inhibitors to prevent acquired resistance through activation of CCDN1. The gene discussed is CCND1; the disease is cancer.